Alimera Sciences, Inc. (ALIM)

NASDAQ: ALIM · IEX Real-Time Price · USD
3.400
-0.020 (-0.58%)
Feb 20, 2024, 4:30 PM EST - Market closed
-0.58%
Market Cap 178.22M
Revenue (ttm) 68.48M
Net Income (ttm) -21.39M
Shares Out 52.42M
EPS (ttm) -2.63
PE Ratio n/a
Forward PE 16.29
Dividend n/a
Ex-Dividend Date n/a
Volume 43,442
Open 3.400
Previous Close 3.420
Day's Range 3.310 - 3.570
52-Week Range 1.300 - 4.380
Beta 1.20
Analysts Strong Buy
Price Target 6.50 (+91.18%)
Earnings Date Apr 1, 2024

About ALIM

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its pr... [Read more]

Sector Healthcare
IPO Date Apr 22, 2010
Employees 150
Stock Exchange NASDAQ
Ticker Symbol ALIM
Full Company Profile

Financial Performance

In 2022, ALIM's revenue was $54.13 million, a decrease of -8.30% compared to the previous year's $59.03 million. Losses were -$18.11 million, 314.2% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ALIM stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 91.18% from the latest price.

Price Target
$6.5
(91.18% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macu...

12 days ago - GlobeNewsWire

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians...

7 weeks ago - GlobeNewsWire

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians...

2 months ago - GlobeNewsWire

Alimera Appoints Maggie A. Pax to Its Board of Directors

ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners con...

3 months ago - GlobeNewsWire

Alimera Sciences Reports Third Quarter 2023 Results

ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners co...

4 months ago - GlobeNewsWire

Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress

ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners con...

4 months ago - GlobeNewsWire

Alimera Sciences Appoints Jason Werner as Chief Operating Officer

ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners co...

5 months ago - GlobeNewsWire

Alimera Sciences Reports Second Quarter 2023 Results

ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners co...

6 months ago - GlobeNewsWire

Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update

ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners conce...

7 months ago - GlobeNewsWire

Alimera Acquires U.S. Commercial Rights to YUTIQ®

ATLANTA, May 18, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concer...

9 months ago - GlobeNewsWire

Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET

ATLANTA, May 17, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concer...

9 months ago - GlobeNewsWire

Alimera Sciences Reports First Quarter 2023 Results

ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners conc...

10 months ago - GlobeNewsWire

Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update

ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concer...

10 months ago - GlobeNewsWire

Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries

Horus to increase ILUVIEN commercial presence with Nordic Retinal Specialists Horus to increase ILUVIEN commercial presence with Nordic Retinal Specialists

11 months ago - GlobeNewsWire

Alimera Sciences Announces 2022 Financial Results and Business Update

• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021

11 months ago - GlobeNewsWire

Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update

Conference Call to be held Friday, March 31, at 9:00am Eastern Time Conference Call to be held Friday, March 31, at 9:00am Eastern Time

11 months ago - GlobeNewsWire

Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®

Switzerland is latest market for Alimera in continued geographic expansion Switzerland is latest market for Alimera in continued geographic expansion

1 year ago - GlobeNewsWire

Alimera Sciences Announces Third Quarter 2022 Financial Results

ATLANTA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners co...

1 year ago - GlobeNewsWire

Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments

Data from the Phase 4 observational real-world safety study of the intravitreal implant were presented at the annual American Academy of Ophthalmology (AAO) conference. Data from the Phase 4 observati...

1 year ago - GlobeNewsWire

Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network

ILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy ILUVIEN or faricimab (6.0 mg) injections versus observ...

1 year ago - GlobeNewsWire

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland

Reimbursement granted with no restrictions to the label Reimbursement granted with no restrictions to the label

1 year ago - GlobeNewsWire

Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress

Positive findings from the RIVER study and data on retreatment with ILUVIEN available Positive findings from the RIVER study and data on retreatment with ILUVIEN available

1 year ago - GlobeNewsWire

Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners con...

1 year ago - GlobeNewsWire

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal

Reimbursement granted with no restrictions to the label Alimera to begin selling later in Q3

1 year ago - GlobeNewsWire

Alimera Sciences Announces Second Quarter 2022 Financial Results

ATLANTA, July 27, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription op...

1 year ago - GlobeNewsWire